Literature DB >> 14736807

Response to allegations and some considerations on interferon treatment in Behçet's disease.

Haluk Demiroglu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14736807      PMCID： PMC1771984     

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  8 in total

Review 1.  Effects of age and sex on Behçet's disease.

Authors:  Y Bardak
Journal:  J Rheumatol       Date:  1999-04       Impact factor: 4.666

2.  Retraction: interferon alfa-2b...in Behçet's disease.

Authors:  R Horton
Journal:  Lancet       Date:  2000-10-14       Impact factor: 79.321

3.  Behçet's disease and interferon: flaws in research integrity of randomised trial.

Authors:  I Sayek
Journal:  Lancet       Date:  2000-10-14       Impact factor: 79.321

4.  Vascular thrombotic problems in Behçet's disease.

Authors:  H Demiroğlu; S Yalçin; Y Büyükaşik; S Dündar
Journal:  Acta Haematol       Date:  1997       Impact factor: 2.195

5.  Assessing the risk of deep vein thrombosis in Behçet's disease.

Authors:  H Demiroğlu; I Barişta; S Dündar
Journal:  Thromb Res       Date:  1996-11-15       Impact factor: 3.944

6.  Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial.

Authors:  H Demiroglu; O I Ozcebe; I Barista; S Dündar; B Eldem
Journal:  Lancet       Date:  2000-02-19       Impact factor: 79.321

7.  Risk factor assessment and prognosis of eye involvement in Behcet's disease in Turkey.

Authors:  H Demiroğlu; I Barişta; S Dündar
Journal:  Ophthalmology       Date:  1997-04       Impact factor: 12.079

8.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Authors:  I Kötter; M Zierhut; A K Eckstein; R Vonthein; T Ness; I Günaydin; B Grimbacher; S Blaschke; W Meyer-Riemann; H H Peter; N Stübiger
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.